Edwards Lifesciences Valuation Multiples

Edwards Lifesciences Overview

About Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Founded

1999

HQ

Employees

16.0K

Website

edwards.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $6B

EBITDA: $2B

EV

$47B

Valuation Multiples

Multiples.vc

Start free trial

Edwards Lifesciences Financials

Edwards Lifesciences reported last 12-month revenue of $6B and EBITDA of $2B.

In the same LTM period, Edwards Lifesciences generated $5B in gross profit, $2B in EBITDA, and $2B in net income.

Edwards Lifesciences P&L

In the most recent fiscal year, Edwards Lifesciences reported revenue of $6B and EBITDA of $2B.

Edwards Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Edwards Lifesciences Stock Performance

Edwards Lifesciences has current market cap of $51B, and enterprise value of $47B.

Edwards Lifesciences' stock price is $87.18.

Edwards Lifesciences Valuation Multiples

Edwards Lifesciences trades at 7.6x EV/Revenue multiple, and 25.1x EV/EBITDA.

Edwards Lifesciences Financial Valuation Multiples

As of April 5, 2026, Edwards Lifesciences has market cap of $51B and EV of $47B.

Equity research analysts estimate Edwards Lifesciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Edwards Lifesciences has a P/E ratio of 32.5x.

Edwards Lifesciences Margins & Growth Rates

Edwards Lifesciences' revenue in the last 12 month grew by 10%.

Edwards Lifesciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Edwards Lifesciences' rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Edwards Lifesciences' rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Edwards Lifesciences Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Edwards Lifesciences M&A Activity

Edwards Lifesciences acquired XXX companies to date.

Last acquisition by Edwards Lifesciences was on XXXXXXXX, XXXXX. Edwards Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Edwards Lifesciences Investment Activity

Edwards Lifesciences invested in XXX companies to date.

Edwards Lifesciences made its latest investment on XXXXXXXX, XXXXX. Edwards Lifesciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).